

Special Issue

Pediatric Cardiomyopathies: From Genotype to Phenotype

Message from the Guest Editors

Cardiomyopathies in children are rare diseases (estimated incidence of ≈ 1 per 100 000 children). They are a major cause of morbidity, and major indications for heart transplantation and mortality. If we compare Children cardiomyopathy to other rare diseases (including cancers), a clear divergence is observed in terms of advances in research and dedicated scientific meetings in the latter group. The main focus of this Issue is to offer an updated landscape and increase knowledge in specific characteristics related to childhood onset cardiomyopathies and to attempt to establish personalized management workflows that can help clinicians when facing specific and sometimes “ultra-rare” cardiomyopathies in children.

Guest Editors

Dr. Anwar Baban

Cardiogenetic Service, Rare Diseases and Medical Genetics Units, Bambino Gesù Children Hospital & Research Institute, IRCCS, 00165 Rome, Italy

Prof. Dr. Sabine Klaassen

Experimental and Clinical Research Center, a cooperation between the Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, and the Charité - Universitätsmedizin Berlin, Lindenberger Weg 80, 13125 Berlin, Germany

Deadline for manuscript submissions

closed (28 February 2022)



Journal of Cardiovascular Development and Disease

an Open Access Journal
by MDPI

Impact Factor 2.3
CiteScore 3.7
Indexed in PubMed



mdpi.com/si/92190

*Journal of Cardiovascular
Development and Disease*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jcdd@mdpi.com

[mdpi.com/journal/
jcdd](https://mdpi.com/journal/jcdd)





Journal of Cardiovascular Development and Disease

an Open Access Journal
by MDPI

Impact Factor 2.3
CiteScore 3.7
Indexed in PubMed



[mdpi.com/journal/
jcdd](https://mdpi.com/journal/jcdd)



About the Journal

Message from the Editor-in-Chief

The primary goal of the *Journal of Cardiovascular Development and Disease* (JCDD, ISSN 2308-3425) is to provide cardiovascular scientists a platform to publish their work in a quick and efficient way. Topics can range from studies designed to decipher the events underlying early heart development to studies focusing on the origins of congenital and acquired heart disease. Papers submitted to JCDD undergo a fast, yet thorough, peer-review process. In this process, we will apply strict ethical policies and standards. JCDD guarantees fast dissemination of results to a large scientific audience

Editor-in-Chief

Prof. Dr. Thomas Brand
National Heart & Lung Institute, Imperial College London, South
Kensington Campus, London SW7 2AZ, UK

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Cardiac and Cardiovascular Systems) /
CiteScore - Q2 (General Pharmacology, Toxicology and
Pharmaceutics)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 28.8 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).